Penicillamine should not be used as initial therapy in Wilson's disease

Movement Disorders

Volumn 14, Issue 4, 1999, Pages 551-554

  Brewer, George J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; PENICILLAMINE; TETRATHIOMOLYBDIC ACID; TRIENTINE; ZINC ACETATE;

ARTICLE; DETERIORATION; DRUG CHOICE; DYSARTHRIA; DYSTONIA; HUMAN; MAINTENANCE THERAPY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SIDE EFFECT; TREMOR; WILSON DISEASE;

CHELATING AGENTS; COPPER; DISEASE PROGRESSION; HEPATOLENTICULAR DEGENERATION; HUMANS; PENICILLAMINE;

EID: 0033455569     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(199907)14:4<551::AID-MDS1002>3.0.CO;2-S     Document Type: Article

References (34)

1. Walshe JM. Penicillamine. A new oral therapy for Wilson's disease. Am J Med 1956;21:487-495.
2. Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1982;1:643-647.
3. Brewer G, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 1987;44:490-493.
4. Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, Tankanow R, Young AB, Kluin KJ. Initial therapy of Wilson's disease patients with tetrathiomolybdate. Arch Neurol 1991;48:42-47.
5. Brewer GJ, Dick RD, Johnson V, et al. Treatment of Wilson's disease with tetrathiomolybdate. I: initial therapy in 17 neurologically affected patients. Arch Neurol 1994;51:545-554.
6. Brewer GJ, Johnson V, Dick RD, Kluin KJ, Fink JK, Brunberg JA. Treatment of Wilson's disease with ammonium tetrathiomolybdate. II: initial therapy in 33 neurologically affected patients and follow-up on zinc therapy. Arch Neurol 1996;53:1017-1025.
7. Brewer G, Hill GM, Prasad AS, Cossack ZT, Rabbani P. Oral zinc therapy for Wilson's disease. Ann Intern Med 1983;99:314-320.
8. Hill GM, Brewer GJ, Prasad AS, Hydrick CR, Hartmann DE. Treatment of Wilson's disease with zinc. I: oral zinc therapy regimens. Hepatology 1987;7:522-528.
9. Hill GM, Brewer GJ, Juni JE, Prasad AS, Dick RD. Treatment of Wilson's disease with zinc. II: validation of oral 64-copper uptake with copper balance. Am J Med Sci 1986;12:344-349.
10. Brewer GJ, Hill GM, Dick RD, et al. Treatment of Wilson's disease with zinc. III: prevention of reaccumulation of hepatic copper. J Lab Clin Med 1987;109:526-531.
11. Brewer GJ, Hill GM, Prasad AS, Dick RD. Treatment of Wilson's disease with zinc. IV: efficacy monitoring using urine and plasma copper. Proc Soc Exp Biol Med 1987;7:446-455.
12. YuzbasiyanGurkan V, Brewer GJ, Abrams GD, Main B, Giacherio D. Treatment of Wilson's disease with zinc. V: changes in serum levels of lipase, amylase and alkaline phosphatase in Wilson's disease patients. J Lab Clin Med 1989;114:520-526.
13. Brewer GJ, YuzbasiyanGurkan V, Lee DY, Appelman H. The treatment of Wilson's disease with zinc. VI: initial treatment studies. J Lab Clin Med 1989;114:633-638.
14. Lee DY, Brewer GJ, Wang Y. Treatment of Wilson's disease with zinc. VII: protection of the liver from copper toxicity by zinc-induced metallothionein in a rat model. J Lab Clin Med 1989;114: 639-645.
15. Brewer GJ, Yuzbasiyan-Gurkan V, Dick R. Zinc therapy of Wilson's disease. VIII: dose response studies. Journal of Trace Elements in Experimental Medicine 1990;3:227-234.
16. Brewer GJ, YuzbasiyanGurkan V, Johnson V. The treatment of Wilson's disease with zinc. IX: response of serum lipids. J Lab Clin Med 1991;118:466-470.
17. YuzbasiyanGurkan V, Grider A, Nostrant T, Cousins RJ, Brewer GJ. The treatment of Wilson's disease with zinc. X: intestinal metallothionein induction. J Lab Clin Med 1992;120:380-386.
18. Brewer GJ, YuzbasiyanGurkan V, Johnson V, Dick RD, Wang Y. Treatment of Wilson's disease with zinc. XI: interaction with other anticopper agents. J Am Coll Nutr 1993;12:26-30.
19. Brewer GJ, YuzbasiyanGurkan V, Johnson V, Dick RD, Wang Y. Treatment of Wilson's disease with zinc. XII: dose regimen requirements. Am J Med Sci 1993;305:199-202.
20. Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, Johnson V, Wang Y. Treatment of Wilson's disease with zinc. XIII: therapy with zinc in presymptomatic patients from the time of diagnosis. J Lab Clin Med 1993;123:849-858.
21. Brewer GJ, Johnson V, Kaplan J. The treatment of Wilson's disease with zinc. XIV: studies of the effect of zinc on lymphocyte function. J Lab Clin Med 1997;129:649-652.
22. Brewer GJ, Dick RD, Johnson VD, Brunberg JA, Kluin KJ, Fink JK. The treatment of Wilson's disease with zinc. XV: long-term follow-up studies. J Lab Clin Med. 1998;132:264-278.
23. Brewer GJ, YuzbasiyanGurkan V. Wilson's disease. Medicine 1992;71:139-164.
24. Hoogenraad TU, Koevoet R, De Ruyter Korver EGWM. Oral zinc sulfate as long-term treatment in Wilson's disease (hepatolenticular degeneration). Eur Neurol 1979;18:205-211.
25. Hoogenraad TU, Van den Hamer CJA, Koevoet R, De Ruyter Korver EGWM. Oral zinc in Wilson's disease. Lancet 1978;ii: 1262-1263.
26. Hoogenraad TU, Van Hatum J, Van den Hamer CJA. Management of Wilson's disease with zinc sulfate. Experience in a series of 27 patients. J Neurol Sci 1987;77:137-146.
27. Nazer H, Ede RJ, Mowat AP, Williams R. Wilson's disease: clinical presentation and use of prognostic index. Gut 1986;27:1377-1381.
28. Nimni ME, Bavetta LA. Collagen defect induced by penicillamine. Science 1965;150:905-907.
29. Roncheti IP, Fornieri C, Contri MB, Quaglino D Jr, Caselgrandi E. Effect of DL-penicillamine on the aorta of growing chickens. Am J Clin Pathol 1986;124:436-447.
30. Shimon I, Sela BA, Moses B, Doley E. Hemolytic episode in a patient with Wilson's disease treated with zinc. Isr J Med Sci 1993;29:646-647.
31. Walshe JM, Munro NAR. Zinc-induced deterioration in Wilson's disease aborted by treatment with penicillamine, dimercaprol, and a novel zero copper diet. Arch Neurol 1995;52:10-11.
32. Mjolnerod OK, Dommerud SA, Rasmussen K, Gjeruldsen ST. Congenital connective tissue defect probably due to D-penicillamine treatment in pregnancy. Lancet 1971;i:673-675.
33. Solomon L, Abrams G, Dinner M, Berman L. Neonatal abnormalities associated with D-penicillamine treatment during pregnancy. N Engl J Med 1977;296:54-55.
34. Keen CL, Lonnerdal B, Hurley LS. Teratogenic effect of copper deficiency and excess. In: Sorenson JRJ, ed. Inflammatory Disease and Copper. Clifton, NJ: Humana Press, 1982:109-121.